← Back to all trials
Active Not Recruiting
NCT07692230
MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer
Conditions: HR Positive/HER-2 Negative Breast Cancer
Sex: Female
Healthy volunteers: No
Enrollment: 2000
Sponsor: Fudan University
Location: Fudan university Shanghai Cancer Center Shanghai Shanghai Municipality
Summary
Luminal breast cancer is characterized by marked heterogeneity, resulting in diverse treatment responses and long-term outcomes. This project aims to integrate MRI and multiomics data to achieve non-invasive molecular typing and precise response prediction. By linking imaging phenotypes with underlying molecular and pathological characteristics, the investigators will develop predictive models for treatment resistance, recurrence, and metastasis, ultimately supporting personalized treatment strategies and precision oncology.
Eligibility Criteria
Inclusion Criteria:
1. Histopathologically confirmed invasive luminal breast cancer (HR+/HER2-);
2. Patients who underwent breast MRI examination.
Exclusion Criteria:
1. Pathological biopsy performed prior to the baseline MRI examination;
2. Patients have received any form of prior treatment for the breast cancer;
3. History of other malignancies;
4. Incomplete or poor-quality MRI and/or pathological images;
5. Missing clinical data.
Source: ClinicalTrials.gov (NCT07692230). StuddyBuddy aggregates publicly available trial information.
